RhumbLine Advisers
ELTX icon

RhumbLine Advisers’s Elicio Therapeutics ELTX Stock Holding History

RhumbLine Advisers’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,170
Closed -$25K – 3138
2022
Q1 		$25K Buy
1,170
+75
+7% +$1.69K ﹤0.01% 3000
2021
Q4 		$32K Hold
1,095
– – ﹤0.01% 2995
2021
Q3 		$107K Buy
+1,095
New +$118K ﹤0.01% 2987

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

RhumbLine Advisers's ELTX Position: Q2 2022 in Review

RhumbLine Advisers sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 1,170 shares — an estimated $25K sold.

RhumbLine Advisers first reported a position in ELTX in Q3 2021 and held it in 3 quarters. The position peaked at $107K in Q3 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

  • RhumbLine Advisers reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 1,170 Elicio Therapeutics shares in Q2 2022, an estimated $25K.
  • RhumbLine Advisers first reported a position in Elicio Therapeutics in Q3 2021 and held it in 3 quarters.
  • RhumbLine Advisers's Elicio Therapeutics position peaked at $107K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.